NCT07302542

Brief Summary

This study intends to recruit 90-100 constipated participants aged 25-50 years, including an equal number of males and females, from the faculty and logistics staff of Capital Medical University. Participants will be randomly divided into an intervention group (55-60 individuals) and a control group (35-40 individuals). The intervention group will consume 250 mL of Mengniu Daily Fiber Oat Milk daily for 4 weeks, while the control group will not receive oat milk intervention. Both groups will maintain their original lifestyles, including diet, sleep, and exercise, throughout the study period. Baseline surveys, dietary surveys, blood and urine routine tests, blood biochemical indices, and intestinal flora detection will be conducted before and after the intervention. Defecation status will be recorded, and gastrointestinal symptoms will be assessed using a Gastrointestinal Symptom Rating Scale. Statistical analysis will be performed to determine the laxative efficacy of oat milk.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Dec 2025

Shorter than P25 for not_applicable

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 30, 2025

Completed
15 days until next milestone

Study Start

First participant enrolled

December 15, 2025

Completed
9 days until next milestone

First Posted

Study publicly available on registry

December 24, 2025

Completed
22 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 15, 2026

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 15, 2026

Completed
Last Updated

December 24, 2025

Status Verified

December 1, 2025

Enrollment Period

1 month

First QC Date

November 30, 2025

Last Update Submit

December 11, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Changes in Intestinal Flora Composition Assessed by Metagenomic Sequencing

    Fecal samples from a randomly selected subgroup (30 participants in the intervention group and 15 in the control group) will be collected before and after the intervention. Metagenomic sequencing will be used to evaluate changes in intestinal microbiota composition and functional gene pathways, including metabolism-, immunity-, and disease-related gene sets. This outcome explores potential mechanisms by which the intervention exerts laxative effects.

    Collect feces and evaluate at baseline and at the fourth week.

Secondary Outcomes (1)

  • Changes in Gastrointestinal Symptoms Assessed by the Gastrointestinal Symptom Rating Scale

    Participates will fill out the questionnaire at baseline, Week 2, and Week 4.

Study Arms (2)

Intervention Group

EXPERIMENTAL
Dietary Supplement: oat milk

Control Group

NO INTERVENTION

Interventions

oat milkDIETARY_SUPPLEMENT

The intervention group will consume 250 mL of Mengniu Daily Fiber Oat Milk daily for 28 consecutive days

Intervention Group

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Clinical diagnosis of non-organic and habitual constipation;
  • Reduced defecation frequency;
  • Increased stool hardness;
  • Fewer than 4 bowel movements per week;

You may not qualify if:

  • Inability to take food orally or inability to comply with the required intake of the test product;
  • Known allergy to oats or related products;
  • Unclear primary gastrointestinal complaints;
  • Physical weakness that prevents participation in the trial;
  • History of surgery within the past 30 days that may cause constipation;
  • Recent constipation caused by severe organic gastrointestinal lesions (e.g., colon cancer, severe enteritis, intestinal obstruction, inflammatory bowel disease);
  • Constipation accompanied by significant abdominal pain;
  • Acute gastrointestinal diseases within the past 30 days;
  • Severe systemic diseases involving the cardiovascular, hepatic, renal, or hematopoietic systems;
  • Ongoing treatment for comorbid conditions that may interfere with study participation;
  • Recent use of substances related to the tested function that may influence outcome measurements.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Constipation

Condition Hierarchy (Ancestors)

Signs and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Xiuwen Ren, PH.D.

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctoral Student

Study Record Dates

First Submitted

November 30, 2025

First Posted

December 24, 2025

Study Start

December 15, 2025

Primary Completion

January 15, 2026

Study Completion

February 15, 2026

Last Updated

December 24, 2025

Record last verified: 2025-12

Data Sharing

IPD Sharing
Will not share